comparemela.com
Home
Live Updates
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019 : comparemela.com
Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
Anders Olsen and colleagues explore patenting on insulin products by the Federal Drug Agency (FDA) and the impact on market exclusivity and drug prices.
Related Keywords
Australia ,
United States ,
Canada ,
Japan ,
Eli Lilly ,
Mylan Semglee ,
Lilly Humalog ,
Sanofi Lantus ,
Lilly Basaglar ,
Sanofi Admelog ,
Lilly Rezvoglar ,
National Heart ,
Drug Administration ,
European Patent Office ,
Trademark Office ,
Us Court ,
Virginia University Hodges Research Grant ,
World Health Organization ,
Alosa Health ,
Obrien Institute Of Public Health ,
European Union ,
Microsoft ,
Commonwealth Fund ,
Rr Core Team ,
Blood Institute ,
Novo Nordisk ,
Office Of The ,
National Bureau For Economic Research ,
Napproved Drug Products ,
Therapeutic Equivalence Evaluations ,
Orange Book ,
New Drug Application ,
Google Patents ,
Cosmetic Act ,
Creative Commons Attribution License ,
Drug Products ,
Arnold Ventures ,
O Brien Institute ,
Public Health ,
West Virginia University ,
Hodges Research Grant ,
Assistant Secretary ,
Editorial Board ,
National Bureau ,
Economic Research ,
Therapeutics Equivalence Evaluations ,
Orange Books ,
Review Board ,
Inflation Reduction Act ,
First Circuit ,
Federal Trade Commission ,
Abbreviated New Drug Applications ,
Biologics Licensing Applications ,
Purple Book ,
Insulin ,
Drug Prices ,
Drug Regulation ,
Diabetes Mellitus ,
Patents ,
Drug Discovery ,
Patients ,
comparemela.com © 2020. All Rights Reserved.